Programmed Death-Ligand 1 (PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma

BACKGROUND: Effective treatments for cholangiocarcinoma (CCA) are still lacking. There are promising results of checkpoint inhibitor programmed cell death ligand-1 (PD-L1) activities in early phase trials. This study aimed to investigate the expression of PD-L1 and its relation to possible treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangkhamanon, Sakkarn, Jongpairat, Piangpen, Sookprasert, Aumkhae, Wirasorn, Kosin, Titapun, Attapol, Pugkhem, Ake, Ungareevittaya, Piti, Chindaprasirt, Jarin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373788/
https://www.ncbi.nlm.nih.gov/pubmed/28670887
http://dx.doi.org/10.22034/APJCP.2017.18.6.1671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373788/
https://www.ncbi.nlm.nih.gov/pubmed/28670887
http://dx.doi.org/10.22034/APJCP.2017.18.6.1671

Ejemplares similares